Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height

Show full item record



Permalink

http://hdl.handle.net/10138/301384

Citation

Varimo , T , Toiviainen-Salo , S , Raivio , T , Kerttula , L , Dunkel , L & Hero , M 2019 , ' Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height ' , Frontiers in Endocrinology , vol. 10 , 201 . https://doi.org/10.3389/fendo.2019.00201

Title: Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height
Author: Varimo, Tero; Toiviainen-Salo, Sanna; Raivio, Taneli; Kerttula, Liisa; Dunkel, Leo; Hero, Matti
Contributor: University of Helsinki, Raivio Group
University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Department of Physiology
University of Helsinki, Department of Diagnostics and Therapeutics
University of Helsinki, Raivio Group
Date: 2019-04-05
Language: eng
Number of pages: 6
Belongs to series: Frontiers in Endocrinology
ISSN: 1664-2392
URI: http://hdl.handle.net/10138/301384
Abstract: Background: Aromatase inhibitors (Als) have been used in boys with idiopathic short stature (ISS) to promote growth despite the lack of actual data regarding treatment effect on adult height. In this study, we characterized adult heights and long-term follow-up in Al-treated boys with ISS. Methods: Adult heights and long-term follow-up data, including spine MRIs, of a randomized, double-blind, placebo-controlled trial of boys who were treated with letrozole (Lz) (2.5 mg/d) or placebo (PI) for 2 years during prepuberty and early puberty. The mean bone ages at treatment cessation were 10.2 and 10.8 years, respectively. Results: Adult heights were similar between the boys treated with Lz (n = 10) and those who received PI (n = 10) (164.8 +/- 4.0 vs. 163.7 +/- 3.7 cm, p = 0.49, respectively). In either group, the adult heights did not differ from predicted adult heights at start of the study [PI: 163.7 (3.7) cm vs. 166.9 (3.3), p = 0.06; Lz: 164.8 (4.0) cm vs. 167.6 (7.9), p = 0.20, respectively]. Long-term follow-up data showed that the frequency of subjects with a vertebral deformity was similar between the groups (Lz, 29% and PI, 22%, p = 0.20), and no single comorbidity was clearly enriched in either group. Conclusions: The Lz-treated boys had similar adult heights with the subjects who received PI for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.
Subject: idiopathic short stature
letrozole
adult height
long-term follow-up
MRI
AROMATASE INHIBITOR THERAPY
IDIOPATHIC SHORT STATURE
VERTEBRAL MORPHOLOGY
GROWTH-HORMONE
CONSTITUTIONAL DELAY
MALES
TESTOSTERONE
ANASTROZOLE
TRIAL
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
fendo_10_00201.pdf 197.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record